Advance amount related to milestone payment.

No definition available.

Name:	LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount related to milestone payment.

+ References

No definition available.

+ Details

Name:	LIXT_AmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Consulting and advisory quarterly cash fee.

+ References

No definition available.

+ Details

Name:	LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Estimated work cost.

+ References

No definition available.

+ Details

Name:	LIXT_EstimatedWorkCost
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of expected paymen through software.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentThroughSoftware
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Expected payment in services.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentinServices
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reimbursement expense.

+ References

No definition available.

+ Details

Name:	LIXT_ReimbursementExpense
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty payable.

+ References

No definition available.

+ Details

Name:	LIXT_RoyaltyPayable
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royaties percentage

+ References

No definition available.

+ Details

Name:	LIXT_RoyatiesPercentage
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Work order agreement costs.

+ References

No definition available.

+ Details

Name:	LIXT_WorkOrderAgreementCosts
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_DeferredCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 30
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478201/954-450-30-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 30
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478201/954-450-30-3

+ Details

Name:	us-gaap_HealthCareOrganizationHealthCareCostsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_InventoryPartsAndComponentsNetOfReserves
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_LitigationSettlementExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details Narrative)								1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Narrative)	Jul. 08, 2024 USD ($)	Feb. 23, 2024 USD ($)	Aug. 27, 2023 USD ($)	Jun. 22, 2023 USD ($)	Feb. 05, 2021 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Apr. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jan. 31, 2030 USD ($)	Mar. 11, 2025 USD ($)	Dec. 31, 2024 USD ($)	Oct. 04, 2024 EUR (€)	Oct. 03, 2023 EUR (€)	Oct. 08, 2021 EUR (€)
Loss Contingencies [Line Items]
Aggregate commitments expected									$ 292,000		$ 292,000
Research and development costs									50,696	$ 361,630	202,801	$ 691,402
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment											685,107
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee							$ 4,000		4,000		12,000
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									510,000		510,000
Clinical Trial Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									292,000		292,000
Clinical Trial Monitoring Agreements [Member]
Loss Contingencies [Line Items]
Contractual commitment									218,000		218,000
Aggregate commitments expected									53,000		53,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Litigation settlement expense	$ 207,004										0	78,015
Total costs									732,532		732,532
Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Inventory costs									1,144,000		1,144,000
Aggregate commitments expected									292,000		292,000
Research and development costs									0	0	0	0
Collaboration Agreement [Member] \| Bio Pharma Works LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee						$ 10,000
Reimbursed expense									13,600	8,000	38,400	35,200
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Research and development costs											695,918
Development Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														$ 3,095,000
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected \| €																€ 100,000	€ 500,000	€ 391,000
Advance amount related to milestone payment									0	76,278	0	210,362
Clinical Trial Research Monitoring [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									74,000		74,000
Research and development costs									4,942	12,610	16,834	20,838
Work order agreement costs									95,000		95,000
Clinical Trial Research Monitoring [Member] \| MD Anderson Cancer Center Clinical [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									43,597		43,597
Clinical Trial Research Monitoring [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs									4,500	14,900	13,500	14,900
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Total costs									61,058		61,058
Aggregate commitments expected									91,000		91,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Total costs									87,823		87,823
Research and development costs					$ 335,000				0	1,603	0	10,603
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Total costs									33,691		33,691
Research and development costs									3,981	13,475	11,603	26,207
Work cost			$ 106,380	$ 153,000
Percentage of payment through services			47.00%	72.00%
Percentage of payment through software				28.00%
License Agreement [Member]
Loss Contingencies [Line Items]
Non refundable license issue royalty		$ 50,000
Minimum annual royalty payable															$ 30,000
Dosing of product		100,000
Payment for royalties		$ 1,225,000
Royalty percentage		5.00%
License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Non refundable license issue royalty								$ 50,000
License Agreement [Member] \| Due Each January 1 [Member]
Loss Contingencies [Line Items]
Minimum annual royalty payable		$ 25,643						$ 25,643					$ 30,000
Licensing Agreements [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									1,765,000		1,765,000
Research and development costs											97,835
Research and development process costs									7,397	7,537	22,191	68,106
MRI Global [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									84,000		84,000
Research and development costs											382,579
Advance amount related to milestone payment									$ 7,200	$ 9,062	$ 42,057	$ 18,932